Cargando…

KRAS and BRAF genotyping of synchronous colorectal carcinomas

v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) genotyping is required prior to anti-epidermal growth factor receptor monoclonal antibody therapy administered in cases of metastatic colorectal carcinoma (CRC). Thus, KRAS mutation screening is required for patient management. The present...

Descripción completa

Detalles Bibliográficos
Autores principales: GIANNINI, RICCARDO, LUPI, CRISTIANA, LOUPAKIS, FOTIOS, SERVADIO, ADELE, CREMOLINI, CHIARA, SENSI, ELISA, CHIARUGI, MASSIMO, ANTONIOTTI, CARLOTTA, BASOLO, FULVIO, FALCONE, ALFREDO, FONTANINI, GABRIELLA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997682/
https://www.ncbi.nlm.nih.gov/pubmed/24765171
http://dx.doi.org/10.3892/ol.2014.1905
_version_ 1782313216828768256
author GIANNINI, RICCARDO
LUPI, CRISTIANA
LOUPAKIS, FOTIOS
SERVADIO, ADELE
CREMOLINI, CHIARA
SENSI, ELISA
CHIARUGI, MASSIMO
ANTONIOTTI, CARLOTTA
BASOLO, FULVIO
FALCONE, ALFREDO
FONTANINI, GABRIELLA
author_facet GIANNINI, RICCARDO
LUPI, CRISTIANA
LOUPAKIS, FOTIOS
SERVADIO, ADELE
CREMOLINI, CHIARA
SENSI, ELISA
CHIARUGI, MASSIMO
ANTONIOTTI, CARLOTTA
BASOLO, FULVIO
FALCONE, ALFREDO
FONTANINI, GABRIELLA
author_sort GIANNINI, RICCARDO
collection PubMed
description v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) genotyping is required prior to anti-epidermal growth factor receptor monoclonal antibody therapy administered in cases of metastatic colorectal carcinoma (CRC). Thus, KRAS mutation screening is required for patient management. The present study reported the experience of KRAS/v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutational screening on synchronous CRC pairs from 26 patients, which were defined as index lesions (ILs) and concurrent lesions (CLs) on the basis of tumor grade and dimension and their respective lymph node and distant metastases. Overall, KRAS mutations were present in 38.4% of patients, whereas BRAF mutations were present at a frequency of 11.5%. The genotyping of paired synchronous carcinomas indicated that 11 patients (42.3%) exhibited discordant KRAS mutational statuses in terms of the presence of a mutation in only one lesion of the pair or of two different mutations harbored by each lesion. BRAF mutations were present in the synchronous tumors of two cases, whereas in two other cases, only the IL or CL harbored mutant BRAF. Overall, the mutational statuses of distant and lymph node metastases confirm the genetic heterogeneity of synchronous primary tumors. These results highlighted the fact that adequate sampling and comprehensive testing, when feasible, is likely to optimize the decision-making process for treatment approaches, even in the relatively rare event of multiple synchronous lesions.
format Online
Article
Text
id pubmed-3997682
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-39976822014-04-24 KRAS and BRAF genotyping of synchronous colorectal carcinomas GIANNINI, RICCARDO LUPI, CRISTIANA LOUPAKIS, FOTIOS SERVADIO, ADELE CREMOLINI, CHIARA SENSI, ELISA CHIARUGI, MASSIMO ANTONIOTTI, CARLOTTA BASOLO, FULVIO FALCONE, ALFREDO FONTANINI, GABRIELLA Oncol Lett Articles v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) genotyping is required prior to anti-epidermal growth factor receptor monoclonal antibody therapy administered in cases of metastatic colorectal carcinoma (CRC). Thus, KRAS mutation screening is required for patient management. The present study reported the experience of KRAS/v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutational screening on synchronous CRC pairs from 26 patients, which were defined as index lesions (ILs) and concurrent lesions (CLs) on the basis of tumor grade and dimension and their respective lymph node and distant metastases. Overall, KRAS mutations were present in 38.4% of patients, whereas BRAF mutations were present at a frequency of 11.5%. The genotyping of paired synchronous carcinomas indicated that 11 patients (42.3%) exhibited discordant KRAS mutational statuses in terms of the presence of a mutation in only one lesion of the pair or of two different mutations harbored by each lesion. BRAF mutations were present in the synchronous tumors of two cases, whereas in two other cases, only the IL or CL harbored mutant BRAF. Overall, the mutational statuses of distant and lymph node metastases confirm the genetic heterogeneity of synchronous primary tumors. These results highlighted the fact that adequate sampling and comprehensive testing, when feasible, is likely to optimize the decision-making process for treatment approaches, even in the relatively rare event of multiple synchronous lesions. D.A. Spandidos 2014-05 2014-02-21 /pmc/articles/PMC3997682/ /pubmed/24765171 http://dx.doi.org/10.3892/ol.2014.1905 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
GIANNINI, RICCARDO
LUPI, CRISTIANA
LOUPAKIS, FOTIOS
SERVADIO, ADELE
CREMOLINI, CHIARA
SENSI, ELISA
CHIARUGI, MASSIMO
ANTONIOTTI, CARLOTTA
BASOLO, FULVIO
FALCONE, ALFREDO
FONTANINI, GABRIELLA
KRAS and BRAF genotyping of synchronous colorectal carcinomas
title KRAS and BRAF genotyping of synchronous colorectal carcinomas
title_full KRAS and BRAF genotyping of synchronous colorectal carcinomas
title_fullStr KRAS and BRAF genotyping of synchronous colorectal carcinomas
title_full_unstemmed KRAS and BRAF genotyping of synchronous colorectal carcinomas
title_short KRAS and BRAF genotyping of synchronous colorectal carcinomas
title_sort kras and braf genotyping of synchronous colorectal carcinomas
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997682/
https://www.ncbi.nlm.nih.gov/pubmed/24765171
http://dx.doi.org/10.3892/ol.2014.1905
work_keys_str_mv AT gianniniriccardo krasandbrafgenotypingofsynchronouscolorectalcarcinomas
AT lupicristiana krasandbrafgenotypingofsynchronouscolorectalcarcinomas
AT loupakisfotios krasandbrafgenotypingofsynchronouscolorectalcarcinomas
AT servadioadele krasandbrafgenotypingofsynchronouscolorectalcarcinomas
AT cremolinichiara krasandbrafgenotypingofsynchronouscolorectalcarcinomas
AT sensielisa krasandbrafgenotypingofsynchronouscolorectalcarcinomas
AT chiarugimassimo krasandbrafgenotypingofsynchronouscolorectalcarcinomas
AT antoniotticarlotta krasandbrafgenotypingofsynchronouscolorectalcarcinomas
AT basolofulvio krasandbrafgenotypingofsynchronouscolorectalcarcinomas
AT falconealfredo krasandbrafgenotypingofsynchronouscolorectalcarcinomas
AT fontaninigabriella krasandbrafgenotypingofsynchronouscolorectalcarcinomas